Helsinn

Helsinn is a third-generation, family-owned, global pharmaceutical company with a 50-year track record, specializing in supportive care and oncology. It leverages a fully integrated business model encompassing development, manufacturing, and commercialization, supported by a state-of-the-art manufacturing facility in Ireland. The company has a direct commercial footprint in the U.S. and partners to reach approximately 90 countries, with a core strategic focus on sustainable growth and ESG principles. Its established portfolio and pipeline are centered on addressing unmet needs in cancer supportive care and rare diseases.

Integrated technical organization covering development, regulatory affairs, manufacturing, and supply chain, combining internal expertise with external capabilities. Recently augmented by AI-driven drug discovery collaboration.

Helsinn competes in the supportive care segment with large pharmaceutical companies and specialty pharma firms. Its integrated model and focus on later-stage development differentiate it from early-stage biotechs, but it faces competition from both generic and branded products in the CINV and broader supportive care markets.